陈丽新
【摘要】 目的 观察并分析帕金森病运动障碍患者联合应用司来吉兰与左旋多巴的临床效果。方法 84例帕金森病运动障碍患者作为研究对象, 随机分为对照组与观察组, 各42例。所有患者静脉滴注乙酰谷酰胺与精氨酸, 在此基础上给予对照组盐酸普拉克索与左旋多巴治疗, 观察组则联合应用司来吉兰与左旋多巴治疗, 对两组患者的治疗效果进行统计与评价。结果 治疗前, 两组患者的帕金森综合评分量表(UPDRS)评分比较差异无统计学意义(P>0.05);治疗第2、4、8周后, 两组患者UPDRS评分均较治疗前有所降低, 且观察组UPDRS评分显著低于同时期的对照组患者, 差异具有统计学意义(P<0.05)。经过为期8周的治疗, 观察组患者治疗总有效率为90.5%, 显著高于对照组的73.8%, 差异具有统计学意义(P<0.05)。结论 通过对帕金森病运动障碍患者展开司来吉兰联合左旋多巴治疗, 可有效改善患者的临床症状, 疗效可靠, 值得临床推广及应用。
【关键词】 帕金森病运动障碍;司来吉兰;左旋多巴
DOI:10.14163/j.cnki.11-5547/r.2017.21.065
Application effect of selegiline combined with levodopa in Parkinson's disease movement disorder CHEN Li-xin. Department of Neurology, Liaoning Dandong Central Hospital, Dandong 118000, China
【Abstract】 Objective To observe and analyze the clinical effect of selegiline combined with levodopa in patients with Parkinson's disease movement disorder. Methods A total of 84 patients with Parkinsons disease movement disorder as study subjects were randomly divided into control group and observation group, with 42 cases in each group. All patients was treated with intravenous infusion of aceglutamide and arginine, and the control group was also treated with pramipexole hydrochloride and levodopa for treatment. The observation group was also treated with levodopa and selegiline for treatment. The treatment effect was evaluated in two groups. Results Before treatment, both groups had no statistically significant difference in unified Parkinsons disease rating scale (UPDRS) score (P>0.05). After 2, 4 and 8 weeks of treatment, both groups had lower UPDRS score than that of before treatment, and the observation group was obviously lower than the control group. Their difference had statistical significance (P<0.05). After 8 weeks of treatment, the observation group had significantly higher total treatment effective rate as 90.5% than 73.8% in the control group, and the difference had statistical significance (P<0.05). Conclusion For patients with Parkinsons disease movement disorder, combined therapy of selegiline and levodopa can effectively improve the clinical symptoms of patients and reliable efficacy. So it is worthy of clinical promotion and application.
【Key words】 Parkinsons disease movement disorder; Selegiline; Levodopa
作为临床一种常见的中枢神经系统疾病, 帕金森病又被称为震颤麻痹, 其病理变化主要为黑体及纹状体中的多巴胺能神经元出现了变性情况[1]。此类疾病多发于60岁以上的人群, 其临床表现主要为肌强直、震颤、共济失调以及进行性运动障碍等。现阶段, 临床在治疗帕金森病患者时, 通常采用左旋多巴的治疗方法, 可明显改善患者的运动功能, 但由于其作用机制的原因, 會造成较严重的不良反应[2]。在此种形势下, 为解决长期单一应用左旋多巴治疗造成的不利影响, 促进疗效的改善, 就需要探寻出作用机制不同但药理作用相同的药物与之联用[3]。基于此, 本文以本院84例帕金森病运动障碍患者为例, 对联合应用司来吉兰与左旋多巴的效果展开探讨。具体……